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Editorial
Can more breasts be saved if chemotherapy and radiotherapy
are administered concomitantly?
Surgery and radiotherapy are local treatments, and their
proponents rightly insist on the importance of their
modalities in assuring loco-regional control in breast
cancer. Since the local effects of systemic therapies are
less marked than those of surgery and radiotherapy, the
former are often not taken into account in planning
local-regional treatment strategies. In particular, the
decision regarding conservation versus amputation of the
breast is frequently contingent upon obtaining micro-
scopically negative lumpectomy margins, with little
consideration of other parameters.
It is axiomatic that the risk of ipsilateral breast
tumour recurrence (IBTR) is greater in the presence
than in the absence of involved margins, as a somewhat
greater percentage of margin-positive patients may have
a residual tumour burden that is too extensive to be totally
eliminated by radiotherapy. Thus it is not surprising that
the recent literature regarding breast conservation has
been dominated by the issue of resection margins. A
cursory search of the English-language literature since
1994 reveals 152 publications devoted to some aspect of
this problem, with fully 40 of them featuring 'margins'
in their titles. This current 'margin mania' has both
positive and negative consequences. On the one hand, it
reflects a healthy concern for quality assurance in breast-
conserving surgery and has probably contributed to a
reduction in IBTR rates compared with those observed
during the 1970s. On the other hand, margins are coming
to be viewed as an end in themselves, resulting in patients
undergoing questionably useful operations, including
total mastectomy, simply to re-excise 'close' margins. It
will be of considerable practical importance to define
under what conditions excision margins status should
legitimately influence clinical decision making.
The study of Assersohn et al. [1] in the current issue
of this journal addresses the question as to whether or
not lumpectomy margin status is clinically relevant
in patients receiving breast irradiation concomitantly
with chemoendocrine treatment. This paper analyses a
subgroup of 184 conservatively-operated patients from a
previously published trial comparing the results of eight
courses of chemotherapy (mitozantrone and metho-
trexate, with inclusion of mitomycin-C in a minority of
patients) given postoperatively with those of the same
chemotherapy administered as a 'sandwich', half before
and half following surgery. All patients received
tamoxifen regardless of receptor status, and irradiation
was started four to six weeks after surgery, concurrently
with chemotherapy. After a median follow-up of 5 years
the main findings of the study were, firstly, that local
control was very high, with only 6 of 184 patients (3%)
observed to have suffered IBTR (only 2 as first site of
relapse), despite the fact that 38% of patients had micro-
scopically positive excision margins. Secondly, although
there were slightly more IBTRs when margins were
involved, this difference was statistically insignificant
and of little clinical importance. Only 2 of the 70 patients
with positive margins had IBTR as first site of failure, a
result that could hardly have been bettered by a more
aggressive surgical approach. As might be expected in
such a small study, there were no differences in outcome
according to chemotherapy sequencing, nor did margin
involvement seem to affect metastatic or survival rates.
Despite the small size of the study, these results from
the Royal Marsden Hospital are provocative, especially
in the light of the increasing use of chemoendocrine
therapies and the importance attached to breast preser-
vation in many Western countries. These data, along
with those from other prospective trials, indicate that
the question of systemic treatment, and possibly its
sequencing with respect to radiotherapy, could be con-
structively integrated into decision making regarding
surgical management. Data from randomised trials
clearly indicate that IBTR rates are significantly lower
when radiotherapy is associated with tamoxifen and/or
chemotherapy. Under presumably optimal 'low risk'
conditions of node-negative early breast cancer excised
with microscopically clear margins, modern radiotherapy
(even including a boost to the tumour bed) can at best
achieve an IBTR rate of 1% per annum in the absence of
systemic therapy [2, 3]. In oestrogen receptor-positive
tumours long-term tamoxifen administration reduces
this baseline IBTR rate, at least under these favourable
conditions, to less than 0.5% per year [4, 5].
Given the multiplicity of cytotoxic regimens and their
potential interactions with radiotherapy, the situation
regarding the effects of chemotherapy on IBTR is more
complex. Factors that potentially modulate the inherent
risk of local failure in patients receiving a given chemo-
therapy regimen include the delay in starting radiotherapy
imposed by chemotherapy administration, and the timing
of radiotherapy with respect to systemic treatment. This
can be illustrated from the trails of the National Surgical
Adjuvant Breast and Bowel Project (NSABP), whose
data most clearly show the impact of chemotherapy on
IBTR rates (Table 1). In the early NSABP trials, breast
irradiation was begun after the first cycle of chemo-
therapy and further chemotherapy was not delayed dur-
ing the five weeks of radiation treatment [2]. Despite
chemotherapy regimens that might be considered sub-
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Table I. Ipsilateral breast tumour recurrence (IBTR) in trials of
the National Surgical Adjuvant Breast and Bowel Project in patients
receiving 50 Gy breast irradiation after breast-conserving surgery,
according to the sequencing of adjuvant chemotherapy
Sequence Trials [references] IBTR rate
No chemotherapy B-06, B-13. B-14 [5-7] 1008 1.5%-2%/year
Sequential B-15, B-18, B-22 [2, 8. 9] 1764 > 1%/year
Concomitant B-06, B-13, B-15, B-19 903 ~0.5%/year
[2, 6,7]
standard today, these studies were distinguished by very
low IBTR rates. In the B-06 Trial the 12-year IBTR rate
was 5% in 192 node-positive patients receiving melphalan
and 5-fluorouracil concomitantly with 50 Gy breast
irradiation [6]. Similarly, in node-negative, oestrogen
receptor-negative patients 50 Gy breast irradiation
started just after the first cycle of chemotherapy led to
an eight-year IBTR rate of 3% in 116 patients receiving
methotrexate, 5-fluorouracil, and leucovorin, and to a
five-year IBTR rate of 1% in 194 patients receiving CMF
[7]. Such low IBTR rates were never observed in NSABP
patients having the same local treatment without sys-
temic therapy (Table 1). In later studies by the same
group, the introduction of doxorubicin and cyclophos-
phamide (AC) led to a change in the timing of breast
irradiation, which was not only delayed, but was no
longer administered during chemotherapy [2]. In these
studies the observed IBTR rates once again increased
to 1% per annum or more, even though some of the
patients in these later studies also received tamoxifen [2,
8, 9]. Interestingly, in the arm of the B-15 Trial in which
patients received CMF without delaying breast irradia-
tion, the IBTR rate was about half of that observed in
the other two arms in which radiotherapy was given
after completing anthracycline-containing chemotherapy
[2]. Although some of the apparently poorer local con-
trol observed in the AC studies might be attributed to
the inclusion of higher-risk tumours, these results never-
theless raise intriguing questions regarding the temporal
relationship between the treatment modalities.
Radiation oncologists have long been dismayed by the
practice of delaying radiotherapy in patients receiving
chemotherapy after breast-conserving surgery. The only
randomised trial addressing the question of treatment
sequencing, though of insufficient statistical power to be
considered definitive, suggests that delaying breast irra-
diation until after chemotherapy results in some decrease
in local control [10]. The degradation in IBTR rates
observed in NSABP studies since the introduction of
AC chemotherapy may simply be related to an increased
interval between surgery and radiotherapy. However, the
additional delay occasioned by the sequential adminis-
tration of four cycles of AC is relatively short, generally
about five weeks [2]. Consequently the observed effect
may more plausibly be related to the fact that radio-
therapy was administered sequentially rather than con-
comitantly with chemotherapy as in the earlier studies.
The paper of Assersohn et al. adds to the growing
body of studies of various tumour types [11, 12], suggest-
ing that the simultaneous administration of radiother-
apy and chemotherapy leads to superior local control.
Although simultaneous radio-chemotherapy may pose
problems of logistical organisation and acute tolerance,
breast irradiation is feasible in conjunction with CMF
regimens, and does not appear to lead to increased late
effects [13]. Although there is understandable reluctance
to use radiotherapy concomitantly with anthracyclines
in breast cancer, particularly regarding the potential for
increased cardiac toxicity, improvements in radiotherapy
technology [14] should allow safe and effective combina-
tions to be developed, even if they require a modest
reduction in radiation dose or dose per fraction. Con-
comitant combined treatment strategies should be the
object of future prospective trials, with the intention of
both improving breast preservation rates and shortening
the oppressively long treatment programmes to which
patients are sometimes subjected. Moreover, as the Royal
Marsden experience suggests, the methodology as well as
the clinical usefulness of microscopic resection margin
assessment require serious re-evaluation in the setting of
concomitant treatment approaches.
J. M. Kurtz
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